» Articles » PMID: 10220377

Mitochondrial Disease in Mouse Results in Increased Oxidative Stress

Overview
Specialty Science
Date 1999 Apr 29
PMID 10220377
Citations 183
Authors
Affiliations
Soon will be listed here.
Abstract

It has been hypothesized that a major factor in the progression of mitochondrial disease resulting from defects in oxidative phosphorylation (OXPHOS) is the stimulation of the mitochondrial production of reactive oxygen species (ROS) and the resulting damage to the mtDNA. To test this hypothesis, we examined the mitochondria from mice lacking the heart/muscle isoform of the adenine nucleotide translocator (Ant1), designated Ant1(tm2Mgr) (-/-) mice. The absence of Ant1 blocks the exchange of ADP and ATP across the mitochondrial inner membrane, thus inhibiting OXPHOS. Consistent with Ant1 expression, mitochondria isolated from skeletal muscle, heart, and brain of the Ant1-deficient mice produced markedly increased amounts of the ROS hydrogen peroxide, whereas liver mitochondria, which express a different Ant isoform, produced normally low levels of hydrogen peroxide. The increased production of ROS by the skeletal muscle and heart was associated with a dramatic increase in the ROS detoxification enzyme manganese superoxide dismutase (Sod2, also known as MnSod) in muscle tissue and muscle mitochondria, a modest increase in Sod2 in heart tissue, and no increase in heart mitochondria. The level of glutathione peroxidase-1 (Gpx1), a second ROS detoxifying enzyme, was increased moderately in the mitochondria of both tissues. Consistent with the lower antioxidant defenses in heart, the heart mtDNAs of the Ant1-deficient mice showed a striking increase in the accumulation of mtDNA rearrangements, whereas skeletal muscle, with higher antioxidant defenses, had fewer mtDNA rearrangements. Hence, inhibition of OXPHOS does increase mitochondrial ROS production, eliciting antioxidant defenses. If the antioxidant defenses are insufficient to detoxify the ROS, then an increased mtDNA mutation rate can result.

Citing Articles

Skeletal muscle disorders as risk factors for type 2 diabetes.

Tammineni E, Manno C, Oza G, Figueroa L Mol Cell Endocrinol. 2025; 599:112466.

PMID: 39848431 PMC: 11886953. DOI: 10.1016/j.mce.2025.112466.


Metabolism: a potential regulator of neutrophil fate.

Yipeng Z, Chao C, Ranran L, Tingting P, Hongping Q Front Immunol. 2024; 15():1500676.

PMID: 39697327 PMC: 11652355. DOI: 10.3389/fimmu.2024.1500676.


Epi-microRNA mediated metabolic reprogramming counteracts hypoxia to preserve affinity maturation.

Nakagawa R, Llorian M, Varsani-Brown S, Chakravarty P, Camarillo J, Barry D Nat Commun. 2024; 15(1):10516.

PMID: 39627218 PMC: 11615350. DOI: 10.1038/s41467-024-54937-0.


Potential compensatory mechanisms preserving cardiac function in myotubular myopathy.

Simon A, Diedhiou N, Reiss D, Goret M, Grandgirard E, Laporte J Cell Mol Life Sci. 2024; 81(1):476.

PMID: 39625536 PMC: 11615164. DOI: 10.1007/s00018-024-05512-9.


Resolving Phenotypic Variability in Mitochondrial Diseases: Preliminary Findings of a Proteomic Approach.

Cicchinelli M, Primiano G, Servidei S, Ardito M, Percio A, Urbani A Int J Mol Sci. 2024; 25(19).

PMID: 39409059 PMC: 11477128. DOI: 10.3390/ijms251910731.


References
1.
Pitkanen S, Robinson B . Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. J Clin Invest. 1996; 98(2):345-51. PMC: 507436. DOI: 10.1172/JCI118798. View

2.
Trounce I, Kim Y, Jun A, Wallace D . Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol. 1996; 264:484-509. DOI: 10.1016/s0076-6879(96)64044-0. View

3.
Melov S, Hinerfeld D, Esposito L, Wallace D . Multi-organ characterization of mitochondrial genomic rearrangements in ad libitum and caloric restricted mice show striking somatic mitochondrial DNA rearrangements with age. Nucleic Acids Res. 1997; 25(5):974-82. PMC: 146531. DOI: 10.1093/nar/25.5.974. View

4.
Graham B, Waymire K, Cottrell B, Trounce I, Macgregor G, Wallace D . A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat Genet. 1997; 16(3):226-34. DOI: 10.1038/ng0797-226. View

5.
Keller J, Kindy M, Holtsberg F, St Clair D, Yen H, Germeyer A . Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J Neurosci. 1998; 18(2):687-97. PMC: 6792529. View